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 INTRODUCTION 
INTRODUCTION: 
               Ischemic  heart  disease  and  cerebrovascular disease are the most 
common cause of mortality and morbidity worldwide. Over three quarters of 
death and  85 % of disability from cardiovascular disease occurs in developing 
countries. The huge burden of cardiovascular disease in Indian sub-continent is 
due to the huge population and high incidence of prevalence of cardiovascular 
risk factors. Cardiovascular diseases also  manifests 10 years earlier than the 
rest of the world in the Indian population. 
          The incidence of myocardial infarction in India is 64.37/1000 people 
among men aged between 29- 69 years of age. In the recent years India has seen 
a huge transition in its disease burden pattern. The load of communicable and 
non communicable disease is expected to be reversed by 2020.India is on the 
threshold of an epidemic of cardiovascular disease. A recent concern is that the 
incidence of CVD has one up significantly for people in the age group 25 – 69 
years, which means losing more productive people to the disease. Urban India 
has higher prevalence than rural India. 
               Platelets are the main agents in the pathogenesis of many acute 
cardiovascular events. Platelet size and activity can be measured as mean 
platelet volume by automated hemolysers.MPV shows positive correlation with 
 markers of platelet activity like expression of glycoprotein Ib and glycoprotein 
IIb / IIIa receptors. Patients presenting with acute coronary syndromes have 
been shown to have higher values of  MPV than those presenting with stable 
angina or non cardiac chest pain. It has been recognised as an independent risk 
factor of both stroke and acute coronary syndromes. An elevated MPV is also 
poorer outcome in patients with long time follow up. 
                       Diabetes is emerging as a major pandemic worldwide. The 
prevalence of this disease is increasing in a log phase with around 340 lakh  
people around worldwide suffering from this metabolic disorder in 2011 
according to a WHO report. Diabetic patients are more prone to develop both 
micro vascular and macro vascular complications .Diabetics have been shown 
to have increase in the platelet activity .The mean platelet volume measured in 
these patients are found to be in the higher end. This index has been evaluated 
in many studies for its role in the disease process of this metabolic disorder. 
Mean platelet volume has been shown to be positively correlating with HbA1c 
values among diabetics. Diabetes is now considered a cardiovascular disease 
equivalent because of its major contributing role in CAD. 
               Many studies have evaluated the role of Mean Platelet Volume in 
diabetes and acute coronary syndromes separately. In this study we try to 
emphasize the key role of platelets in the pathogenesis of diabetes and acute 
cardiovascular events and its role in predicting long term mortality and 
morbidity. 
  
AIM OF THE STUDY 
PROGNOSTIC SIGNIFICANCE OF MEAN PLATELET VOLUME IN 
PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION 
 
Aims &objectives: I )  To find the association between mean platelet 
volume in patients presenting with Acute STEMI on 
admission. 
                                         II ) To compare this index among diabetics and 
non-diabetics presenting with acute STEMI. 
III) To assess whether this index can be used for long 
term prognosis in patients presenting with STEMI. 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
According to a 2007 expert consensus committee, ACUTE 
MYOCARDIAL INFARCTION is redefined as “the detection of rise and / or 
fall in cardiac Troponin with at leastone of the value above the 99thpercentile of 
the upper reference limit (URL) with an assay with less than 10% coefficient of 
variation at the level of detection along with the evidence of ischemia.Ischemia 
was defined as  
 • Symptoms of ischemia 
• New or presumed new significant ST-segment T wave (ST-T) changes 
or new LBBB 
• Development of pathologic Q waves on the ECG 
• Imaging evidence of new loss of viable myocardium or new regional   
wall motion abnormality 
• Identification of an intracoronary thrombus by angiography or autopsy” 
 
The present approach to patients with ischemic painis to consider them to be 
having either stable angina or acute coronary syndrome (ACS), which 
incorporates unstable angina,non ST segment elevation Myocardial Infarction 
(NSTEMI) and ST segment Elevation Myocardial Infarction (STEMI) 
 
   For the diagnosis of ST elevation MI “ST segment elevation of greater than 0.1 
mV should be present in two or more contiguous leads.In precordial leads V1 to 
V4, a ST segment elevation of 0.2 mV increases the diagnostic accuracy”.There 
are two situations in which coronary reperfusion therapy has been shown to be 
beneficial in the absence of ST elevation in 12 lead eg. This includes 
1. Acute myocardial infarction of the posterior wall    
2. Presence of new onset of  LBBB 
Recent classification of Acute Myocardial Infarction: 
“Type 1: spontaneous myocardial infarction 
Type 2:Myocardial infarction secondary to ischemic imbalance 
Type 3: Myocardial infarction resulting in death when cardiac biomarker values 
are unavailable 
Type 4 a: myocardial infarction related to percutaneous coronary intervention 
(PCI) 
Type 4b: myocardial infarction related to stent thrombosis 
Type 5: myocardial infarction related to coronary bypass grafting” 
 
 
           Nearly all ACS events result from atherosclerotic plaque lesions of the 
coronary vessels. In most circumstances the coronary atherosclerotic lesion is 
associated with superadded thrombosis of the coronary vessels with the rupture 
or erosion of the plaque. Non atherogenic forms of coronary artery disease are  
also seen. 
 
CORONARY ARTERY DISEASE OTHER THAN 
ATHEROSCLEROSIS: 
1.Arteritis ( Kawasaki, SLE, Takayasu arteritis ,  PAN, Rheumatoid arthritis ) 
2.Mechanical injury to coronary vessels 
Laceration 
Thrombosis 
Iatrogenic 
Radiation (radiation therapy for neoplasia) 
3.Coronary artery mural thickening  
 Mucopolysaccharidosis( Hurlers disease ) 
Homocysteinuria 
Amyloidosis 
 Intimal hyperplasia associated with contraceptives or with the postpartum 
period 
4. Luminal narrowing by other mechanisms 
      Prinzmetal angina 
     Spasm after nitroglycerin withdrawal 
     Dissection of the aorta 
     Dissection of the coronary artery 
5. Embolisation  to coronary vessels 
6. Developmental coronary artery anomalies 
7. Oxygen supply demand mismatch 
8. Intravascular thrombosis 
9. Miscellaneous 
Cocaine induced coronary vasospasm 
Contusion injury of myocardium 
When acute coronary atherothrombosis occurs, the resulting 
intracoronary thrombus may partially obstruct the lumen , which usually leads 
to subendocardial ischemia in the absence of ST elevation, or completely 
occlude the vessel wall and cause transmural myocardial ischemia and STEMI. 
Previously before the era of thrombolytic therapy it was a general practise to 
 divide myocardial infarction into Q wave MI and non Q wave MI based on the 
ecg changes that evolve in days. Q waves denote infarcted tissue or  dead tissue. 
The Q wave infarction are synonymous with transmural infarction and non Q 
wave infarctions with subendocardial infarction. However recent studies using 
cardiac MR  has shown that the presence of Q waves is dependant on the extent 
of infarction rather than the depth of  mural infarct. 
The recent classification of  MI into STEMI and NSTEMI is preferable 
because immediate clinical decision of fibrinolysis or PCI depends on the 
presence of diagnostic ST elevation on surface ecg. Hence ecg remains the main 
diagnostic tool in the management of patients presenting with chest pain. The 
cardiac biomarkers and other investigations come into play only when the 
electrocardiogram is inconclusive in making the initial diagnosis 
 
PATHOPHYSIOLOGY : 
Atherosclerotic plaque erosion followed by overlying thrombosis in the 
coronaries is postulated to be the main mechanism accounting for most of the 
acute coronary syndromes 
6 different morphological types of atheromatous plaque have been 
identified. Different types of plaque of different constitution and morphology 
may be found in the vasculature of the same individual. 
 Type 1: lesion is characterised by foam cell infiltration, intimal thickening and 
macrophages infiltration 
Type 2:  In these lesions lipids accumulate in the cytoplasm of infiltrating 
macrophages and smooth muscle cells 
Type 3: In addition to the above changes, there is extracellular deposition of 
lipids.Lipids also accumulate in the connective tissue layer 
 The above three lesions are called early lesions. They are present in 
normal individuals in their early decades of life and are usually produce no 
symptoms.They are more common in areas where there is more shear stress in 
the vessel wall.Certain co morbid conditions like hyperglycemias, elevated 
lipids, smoking accentuate this process  
Type 4 (atheroma) : This lesion is characterised by large lipid core in the 
intima  of the vessel wall. There is also a large inflammatory cell infiltrates. 
Type 5: 
V a - Atheroma with fibrous cap 
                  V b - Atheroma with superadded calcification 
   V c - Fibrosed atheroma 
 
 
 Type 6 (complicated lesion): This represents disrupted type 4 or 5 lesions with 
intramural hemorrhage with or without overlying thrombosis 
 As the atherosclerotic lesions progress they become more and more  
softer. This is due to the increase in the lipid content of the plaque as the plaque 
matures. These softer plaques are more prone to rupture. 
 Early (type 1-3 lesions) are asymptomatic. Type 4 and 5 may be 
associated with angina pectoris, but they can also be asymptomatic. 
Type 4 is usually associated with acute coronary syndrome or 
asymptomatic lesion progression. When the lesion causes significant stenosis 
without sufficient collateralization, it results in acute coronary syndrome. 
After the plaque rupture, the lesion organizes itself either into a chronic 
calcificlesionor fibrotic lesion .These patients may present with chronic stable 
anginal pain. 
 Plaque rupture is not unique to advanced stenosis, it can occur in lesion of 
any size and degree of stenosis based on vascular remodelling. 
 The gradual process by which the atheroma forms over years is 
punctuated by rapid burst of growth in the plaque. Such abrupt episodes account 
for many acute coronary syndromes rather than the chronically developing 
occlusive plaque. 
 
 PHASES OF ATHEROSCLEROTIC PLAQUE GROWTH : 
The growth of atherosclerotic plaque is divided into 5 different phases 
based on the characteristics of the lesion and associated clinical presentation 
PHASE 1 ( Early lesions ) 
Type 1 to 3 
Usually asymptomatic. 
 
PHASE 2 (atheroma) 
Type IV to V a 
Presents with stable angina or sometimes asymptomatic. 
 
PHASE 3      
Complicated nonocclusive lesion 
With mural thrombosis (lesion type 4) 
Asymptomatic sudden progression of lesion 
 
                                 
  PHASE 5 (lesion type Va or Vb ) Stable angina pectoris, or late silent 
occlusion 
PHASE 4 
Complicated lesion with flow 
limiting thrombus (lesion type 6 ) 
Presents with acute coronary 
syndromes 
  
Fig 1. Phases of atherosclerotic plaque growth 
 
FACTORS IMPLICATED IN PLAQUE INSTABILITY AND DISRUPTION: 
1. Factors which are intrinsic to the plaque which makes it more prone for 
rupture includes size, location and lipid content and solidarity of the 
fibrous cap. The cap is weak at its stalk. 
2. Activity of the macrophages, monocytes and T cells in the atherosclerotic 
plaque also has a role in plaque stability. Macrophages and monocytes 
derived foam cells secrete metalloproteinases. They degrade the collagen 
content of the plaque. 
3. The activated macrophages, monocytes and lymphocytes may produce  
inflammatory cytokines which in turn recruit cytokines and produce 
oxidative stress by producing reactive oxygen species. 
 4. There is increased programmed cell death of the smooth muscle cells in 
the mature atherosclerotic lesions. T lymphocytes and macrophages also 
undergo apoptosis in advanced lesion. These factors may weaken the 
plaque. 
 
AFTER PLAQUE RUPTURE : 
 Following rupture of the fibrous cap the more prothrombotic underlying 
denuded materials are exposed to blood circulation. Circulating platelets first 
deposit which directly overlies the disrupted plaque leading to the formation 
of ‘white clot’.Red cells and fibrin deposit over white clot forming red clot. 
 
 Fibrinolytic agents lyse the red clot.When used alone they are 
prothrombotic by the release of thrombin.They should be used in conjunction 
with anti platelet agents and anti coagulants. Thrombin which is a clotting 
factor aids in the conversion of fibrinogen to fibrin and also stimulates platelet 
aggregation.Hence fibrinolysis should be always followed by anti platelet and 
anticoagulant therapy. 
 
 Of the constituents of plaque lipid core has maximum thrombogenicity. 
This increased thrombogenicity is due to the increased expression of factors 
like tissue factor in lipid core.The tissue factor produced by the infiltrating cells 
 in the plaque which via activation of coagulation cascade produce thrombin. 
This leads to thrombus production and vast spectrum of clinical possibilities. 
 
CORONARY ARTERY DISEASE: 
 The most common symptom of patients presenting with coronary artery 
disease is angina or chest pain.Angina may be stable or unstable.The most 
widely used scoring system for angina is Canadian Cardiovascular Association 
classification 
 
CANADIAN CARDIOVASCULAR ASSOCIATION CLASSIFICATION 
OF ANGINA : 
 
“Class 1 : Patients with no pain with ordinary physical activity 
 Class 2 : Patients who present with slight limitation of  physical activity (pain                 
     occurs while climbing stairs, walking, stress  etc ) 
Class  3 : Patients who present with severe limitation of daily activity (pain    
      occurs on minimal exertion ) 
Class 4 : Patients who present with pain at  rest or unable to carry out normal  
     activity without pain.” 
 
 
 STABLE ANGINA:  
 Stable angina is defined as chest pain which occurs during 
exertion,emotion or activity.The pain is usually relieved by rest or nitrates.The 
pain lasts for short periods of time usually less than 10 minutes. 
           Males constitute 70%   of  patients with ischemic cardiac even in greater 
proportion in patients less than 50 years of age. Angina is typically crescendo 
and decrescendo in nature lasts for 2 to 5 mins, radiates to either shoulder or 
arm, to the jaw, root of the neck, epigastrium and teeth. Myocardial chest pain 
usually donot radiate to trapezius and this differentiates it from pericardial chest 
pain Patient cannot pinpoint anginal pain and they typically place a clenched fist 
over the sternum to localise the pain (LEVINE SIGN). Anginal equivalents 
include dyspnoea, nausea, fatigue, retching, faintness etc. 
STRESS TESTING : 
    ELECTROCARDIOGRAPHIC: This is the most commonly employed 
test for the diagnosis of ischemic heart disease and for assessing the risk and 
prognostification of coronary artery disease. The test is carried out by 
incremental increase in external workload and assessing patients ‘ symptoms, 
ecg changes and blood pressure. 
 The test is discontinued when the patient experiences chest pain, 
breathlessness, severe fatigue, ST segment depression >0.2 mV, development of 
ventricular tachycardia, fall in sBP greater than 10 mm Hg. A positive stress test 
 is considered when there is ST segment depression of more than 0.1 mV for 
more than 0.08 sec. Negative exercise testing in which the target heart rate 
(85% of the predicted heart rate for age and sex ) is considered non diagnostic. 
                         However a positive stress test is highly suggestive of   ischemic 
heart disease  in males more than 50 years of age who have typical history of 
chest pain and who develop chest discomfort during stress test. False negative 
stress may be seen in Left circumflex artery occlusion because these changes 
are not recorded in surface ecg. 
                          Contraindication for stress test include rest angina, unstable 
angina in the last 48 hours, severe aortic stenosis, severe pulmonary 
hypertension, acute infective endocarditis, acute myocarditis 
CARDIAC IMAGING : 
      This includes stress myocardial perfusion imaging after the intravenous 
administration of Thallium 201 or 99 m Technetium. Pharmacological stress 
testing includes administration of dobutamine, dipyramidamole or adenosine. 
           Cardiac Magnetic Resonance stress testing is also an effective alternative 
for PET scan, radionuclide or echocardiographic stress testing. 
 
 
  CORONARY ARTERIOGRAPHY :  
            This test visualises the lumina of the coronary arteries and helps in 
ruling out serious coronary obstruction. Indications include  
1. Patients with chronic angina not relieved with medication. 
2. Patients with troublesome symptoms to confirm or rule out diagnosis of 
IHD 
3. Patients with angina who survived cardiac arrest. 
 
UNSTABLE ANGINA : 
                    Unstable angina is defined as  
• Pain occurring at rest – duration > 20min, within one week of first visit 
• New onset angina – ~ Class 2 severity, onset with last 2 months 
• Chest pain which is worsening in quality,duration and frequency. 
• Angina refractory to medical therapy 
 
PATHOPHYSIOLOGY : 
         1.plaque rupture or erosion with superimposed non occlusive thrombus 
         2.dynamic obstruction ( eg.coronary spasm) 
     3.Progressive mechanical obstruction  
         4. UA secondary to increased myocardial oxygen demand and or 
decreased supply. 
                      Patients with ST segment elevation in ECG which is persistent 
usually have total occlusion of the coronary vessels.They usually benefit from 
opening up of the coronary vessels by reperfusion therapy either medical or 
catheter based. 
                        Patients with anginal chest without ST segment elevation in ECG 
usually have partial occlusion of the coronary vessels. They donot benefit from 
reperfusion therapy but they require anti ischemic therapy. 
 Thus the 12-lead ECG remains the main diagnostic tool for the 
management of patients with ACS. 
 
ROLE OF CARDIAC BIOMARKERS : 
                      Myocardial injury can be detected by the presence of  certain 
proteins released from damaged myocardial cells.Cardiac biomarkers with 
enhanced sensitivity has enabled clinicians to identify lower levels of 
myocardial injury. However it must be borne in mind that these biomarkers 
donot provide any insight into the cause of injury.MI is due to myocardial injury 
that results from ischemia. Other non ischemic insults like myocarditis, direct 
myocardial toxins can result in myocardial injury.It is recommended that 
therapy should be initiated immediately without waiting for cardiac biomarker 
assay reports and treatment can be initiated based on clinical presentation and 
electrocardiographic findings in patients presenting with acute chest pain. 
 Cell death with lysis breaks the integrity of the sarcolemmal membrane. 
Intracellular molecules diffuses into the cardiac interstitium  from where they 
are absorbed into capillaries and lymphatics and reach the blood stream.The 
presence of these biomarkers in blood depends on many factors like the location 
of the biomarker inside the cell,its molecular mass,blood flow in the region of 
infarct and the speed of elimination from the bloodstream. 
  An ideal cardiac biomarker should be present in a higher concentration in 
myocytes, specific to myocardium,released early in  injury,released in 
proportion to injury and cheap for testing. 
 
Cardiac biomarkers include: 
• Troponins  
• CKMB 
• Myoglobin  
• Other markers 
Cardiac Troponin : 
              It is the preferred biomarker to detect myocardial injury.It contains 3 
subunits: troponin C, troponion T and troponin I.Troponin is present in actin 
myosin complex and regulates calcium mediated muscle contraction.6 to 8 % of 
TnT and 2 to 3 % of TnI is found in cytosolic pool. Following myocardial 
injury, troponin is first released from cytoplasmic pool followed by release from 
structural pool .Separate genes encode troponins in cardiac and skeletal 
 muscles. This allows specific antibody production for the cardiac forms (cTnT 
and cTnI ), enabling the quantitative  measurement of them. Detection of a rise 
and fall in cardiac troponins in an appropriate clinical setting has become the 
centre of the new diagnostic criteria for MI.  
                  Newer high- sensitivity assays are available for precise measurement 
of very low concentrations of cardiac specific troponin. The term high 
sensitivity troponin is reserved for assays that can detect cardiac troponin in 
more than 50% of an apparent healthy population.These assays are more 
sensitive but lack the specificity for MI.However in multiple studies in patients 
with non traumatic chest pain, the diagnostic accuracy has been increased by 
hsTn assays. 
                    In patients with MI, cardiac troponins begin to rise by 3 hours after 
the onset of chest pain and persist for 7 to 10 days after MI.This prolonged 
persistence allows for late diagnosis of MI.Patients who undergo successful 
recanalisation of  the thrombosed artery also have a rapid rise in troponin levels. 
 
    In the absence of cardiac specific troponin assay, CK MB measured with 
a mass assay is the best alternative.Cardiac muscle has both MM and MB 
isoenzymes of CK. Other tissues like small intestine, tongue, diaphragm, uterus, 
prostate contain small amount of the CK MB isoenzyme. Strenuous exercise can 
cause increase in both total CK and CK MB. Because of this, the cut off value 
 for abnormal elevation of  CKMB is usually set a few units above the upper 
reference limit for a given laboratory. 
 Cardiac troponins and CKMB are said to be increased only if  the  values 
exceed the 99% of a reference control group. Assays that have a level of 
imprecision (i.e., coefficient of variation)of less than 10% at the specific 99th 
percentile cut off  are considered optimal for clinical practice. 
 Indicators of inflammation or activation of coagulation cascade like 
myeloperoxidase, soluble CD40 ligand, IL6, hsCRP, d dimer, prothrombin 
fragment 1 & 2 are elevated before the onset of irreversible injury, however 
they lack the specificity. 
 B –type Natriuretic Peptide, Pregnancy Associated Plasma Protein A 
(PAPP-A) and heart fatty acid binding protein are other biomarkers without  
much sensitivity or specificity. 
 
2007 ACC/AHA guidelines regarding cardiac biomarkers : 
• Cardiac biomarkers  should be measured in all patients presenting with 
acute onset of chest pain (class Ib) 
• Troponin is the preferred  cardiac biomarker( Class 1 B) 
• If  troponin  values measured within 6 hours of onset of chest pain they 
should be repeated 8 to 12 hours later. 
 
 
  
 
Fig 2 : Release of  Cardiac Biomarkers and their serum level 
 
  
 
 
Fig 3 : Cardiac biomarkers in MI 
 
Thrombolysis in Myocardial Infarction (TIMI) Score for ST elevation Acute 
Myocardial Infarction(increase in mortality with increasing score ~40% all 
cause mortality at 14 days for patients requiring urgent revascularization) 
 
• “Diabetes, history of hypertension or angina(1 point) 
• Systolic BP less than 100 mm hg(3 points) 
• HR more than 100 BPM (2 points) 
• Killip class II-IV (2 points) 
• Body weight less than 67 kg (1 point) 
 • ST elevation in anterior leads or left bundle branch block morphology (1 
point) 
• Time at presentation more than 4 hours(1point) 
• Age 
 >=75 years old (3 points) 
65-74 ears old (2points) 
               Less than 65 (0 points) 
KILLIP SCORE : 
Class 1 : no evicence of CHF                       5.1 % mortality  rate 
Class 2 :Rales,increased JVP or S3            13.6 % mortality rate 
Class 3 : Pulmonary edema                         32.2 % mortality rate 
Class 4: Cardiogenic shock                          57.8 % mortality rate 
  
Fig 4 : TIMI score and mortality risk in days 
  
MANAGEMENT : 
 
General considerations  
               ECG should be obtained within 10 minutes of hospital arrival. 
               Presence of ST elevation of  0.1 mV   in 2 contiguous leads  must alert 
the physician for rapid evaluation of reperfusion therapy 
         
    Benchmark standards for medical systems to use when assessing the 
quality of their healthcare and performance  are a door-to-needle time for 
initialisation of thrombolytic therapy  of 30 minutes or less and door-to-balloon  
time of 90 minutes or less for PCI 
 
                   General treatment measures include high dose aspirin, analgesics 
like morphine, nitrates, beta adrenergic blocking agents (in the absence of 
hypotension  sBP< 90 ), bradycardia (HR <60 bpm), Significant atrioventricular 
(AV) block and killip class ii or more . 
 
 
 
 
 MEDICAL THERAPY FOR THE TREATMENT OF ACUTE 
CORONARY SYNDROMES 
 
1. Thrombolytics 
2. Anti platelet agents: 
            Aspirin 
            Adenosine diphosphate antagonists : clopidogrel, ticlopidine 
           Glycoprotein II b/III a antagonists : Abciximab, Ebtifibatide, Tirofiban 
3.Anticoagulants : 
         Heparin either low molecular weight or unfractionated 
4.Antianginals 
            Oxygen 
               Nitrates 
              Beta adrenergic receptor blockers 
5. Other agents  
            Angiotensin converting enzyme inhibitors  
            Statins 
 
 
 THERAPY  PRIOR TO REPERFUSION: 
                 According to 2007 ACC/AHA guidelines, the initial management 
consists of: 
                      It involves rapid triage of the patients. 
                      If the electrocardiogram is inconclusive or the diagnosis is 
doubtful, cardiac biomarkers should be ordered 
                   Patients who have inconclusive ECG and negative biomarkers at 12 
hours should be subjected to stress test at 72 hours. 
 
OXYGEN :  
 Supplemental oxygen by means of nasal canula is advised for all patients 
with MI.When patient presents with acute pulmonary edema or cardiogenic 
shock oxygen administration  of oxygen through aace mask or endotracheal 
tube is indicated. 
 
ANALGESICS: 
MORPHINE:  Still has Class 1 recommendation for STEMI, should be given in 
titrated doses. 
NSAIDs should be avoided in patients presenting with acute STEMI 
 
 ANTI ANGINALS: 
BETA BLOCKERS : 
• BETA BLOCKERS 
• Modified recommendation  
• Oral Beta Blockers should be started as soon as possible, if  there are no 
contra-indications (heart failure, risk of cardiogenic shock)  
• Patients who present with early contra indications should be  re- 
evaluated later for possible use 
• IV B blockers – are used in hypertensive patients with STEMI and it 
should not be administered to patients with heart failure or risk of 
cardiogenic shock. 
• Beta blockers are proved to have both mortality and morbidity benefit 
 
NITRATES: 
           Sublingual nitroglycerin is given to patients with acute  MI  to determine 
whether the ST segment elevation represents coronary vasospasm while 
arrangements for reperfusion is considered.They are particularly useful in the 
management of MI complicated with CHF,ongoing symptoms or 
hypertension.Both oral or intravenous dosing can be used. 
  
ANTIPLATELET THERAPY: 
                          It receives Class I recommendation 
• Aspirin should be given immediately on admission to all patients who 
present with acute STEMI.Enteric coated formulation should be avoided. 
Chewable buccal aspirin is given as 325 mg stat dose followed by a 
maintenance dose lifelong unless there are any contraindications. 
• Higher doses for patients who undergo stenting . 
• CLOPIDOGREL – now recommended in all STEMI patients in addition 
to aspirin, whether undergoing reperfusion or not. Dosage 75mg daily or 
a duration of 14 days 
• In patients < 75yrs – Clopidogrel 300mg loading dose recommended 
long term maintenance therapy should be considered, 75mg daily for 
1year  
• For patients who have been planned for  PCI – aspirin & clopidogrel or 
IV glycoprotein 2b/3a therapy  is recommended 
• Abciximab is used if  there is no delay in angiography/PCI, 
eptifibatide/tirofiban if delayed angiography is planned (LOE B) 
• Abciximab is not recommended if PCI is not planned. 
 
 
 
  
ANTICOAGULANT THERAPY : 
 
                     Unless there is any contraindication patients should be started on 
anticoagulant therapy.Unfractionated heparin given as 60 units /kg bolus 
followed by 12 u/kg infusion.LMWH is an effective alternative. However dose 
adjustments is needed for renal failure patients. 
 
LIMITATION OF INFARCT SIZE : 
 
                    Size of the infarct is an important indicator of prognosis in patients 
with MI. Infarct size limitation is the primary goal in the treatment of MI. In 
addition to saving lives saving myocardium is important in patients presenting 
with STEMI .Spontaneous recanalization of an occluded artery occurs in up to 
1/3 rd of  patients . This delayed spontaneousreperfusion may be beneficial by 
enhancing left ventricular function. Yet, maximal salvage of myocardium is 
done by strategies involvingfibrinolysis and catheter-based reperfusion of the 
occluded coronary artery. 
 
 
 
 
 CONCEPT OF REPERFUSION THERAPY : 
 Rapid opening of the infarct artery and reperfusion of the damaged 
myocardium is the most efficient way of   restoring normal cardiac function. 
The time elapsed for reperfusion therapy greatly affects the amount of salvaged 
myocardium in patients treated with either fibrinolysis or PCI.As the clot 
matures, it becomes resistant to fibrinolytic therapy. In some patients with 
cardiac failure the infarction occurs in a slowly progressive way rather in an 
abrupt fashion. They should be evaluated by careful history to ascertain whether 
they were having recurrent episodes of chest pain.In such patients rigid time 
interval should not be advocated while determining the time interval for 
reperfusion therapy 
 
Fig 5: Initial reperfusion therapy in patients with STEMI 
 
  
Fig 6 : Consequence of reperfusion at various time after coronary adhesion 
 
 Prevention of cell death by revascularisation depends on the severity and 
duration of pre existing ischemia. With earlier restoration of blood flow, the left 
ventricular systolic function, diastolic function and mortality are favourably 
influenced. Presence of Collateral coronary vessels also influence left 
ventricular functioning following reperfusion. A phenomenon called 
Myocardial stunning which is the reversible contractile dysfunction seen after 
successful reperfusion in some patients.  
 
 
 
 
  
REPERFUSION INJURY : 
 
                Although reperfusion is associated with   myocardial salvage, it may 
be accompanied by adverse events termed as Reperfusion Injury. Types of 
reperfusion injury includes : 
1. Lethal reperfusion injury : Here there is death of myocytes following   
reperfusion 
2. Vascular reperfusion injury : Reperfusion induced expansion of zone of no 
reflow and loss of coronary vasodilatory reserve 
3. Stunned myocardium :  myocytes exhibit a period of transient  defective 
contraction following reperfusion 
4. Reperfusion arrythmias : Bursts of VT or VF that occurs within seconds of  
reperfusion. 
 
 Transient sinus bradycardia   and hypotension can occur in some patients 
with inferior wall infarcts. Premature ventricular contractions, accelerated 
idioventricular rythm(AIVR) and non sustained VT are common. When present 
rythm disturbances may actually   indicate successful  reperfusion, but their 
specificity is minimal. Although reperfusion arrhythmias cluster around the time 
of restoration of coronary perfusion, this brief electrical storm is usually 
innocuous and usually no prophylactic or specific   anti arrhythmic therapy is 
 needed unless there is hemodynamic compromise following reperfusion 
arrhythmias. 
 
  Microvasculature damage in the reperfused myocardium leads to 
hemorrhagic infarct, which is more seen with fibrinolytic therapy than with 
catheter based reperfusion. 
 A variety of therapies have been proposed to mitigate the effects of 
reperfusion injury including preservation of microvascular integrity by using 
anti platelets and anti thrombins. These agents minimize embolisation of  
atheroembolic debris and prevent inflammatory damage. Remote conditioning 
which is the induction of   transient ischemia in other vascular beds has been 
associated with a reduction in  reperfusion injury..Another approach is Post 
conditioning ,which involves introducing brief repetitive  episodes of ischemia 
alternating with reperfusion. This activates cellular protective mechanisms 
centering around pro survival kinases. 
  Late reperfusion of the stenosed infarct related artery may also improve 
myocardial function. Poorly contracting myocardium in the zone of infarct 
related artery may contain viable myocytes. The function of this hibernating  
myocardium can be improved  by PCI. 
 
 
 
  
FIBRINOLYTIC THERAPY : 
 
 Fibrinolysis recanalizes the thrombotic occlusion in vessel wall  
associated with STEMI. Patients treated in the initial 1 to 2 hours has the 
maximum benefit. Time is muscle and hence early treatment is associated with 
maximum benefits 
 
The absolute contraindication  for Fibinolytic therapy : 
¾ “Patients with any history ofprevious intracranial bleed. 
¾ Known vascular lesion in brain (e.g., arteriovenous malformation). 
¾ Known  intracranial neoplasm (primary or metastatic). 
¾ Ischemic stroke within 3 months except acute ischemic stroke within  
4.5 hours 
¾ Suspected aortic dissection.. 
¾ Active bleeding or bleeding diathesis (excluding menses). 
¾ Significant closed-head or facial trauma within 3 months. 
¾ Intracranial or intraspinal surgery within 2 months. 
¾ Severe uncontrolled hypertension (unresponsive to emergency therapy). 
¾ For streptokinase, previous treatment within the previous 6 months.” 
 
  All fibrinolytic agents exert their effect by converting the inactive 
plasminogen to the active enzyme plasmin. Fibrin specific fibrinolytics are 
those that are inactive in the absence of fibrin and substantially increases its 
activity on plasminogen in its presence. The tissue plasminogen activator 
molecule contains 5 domains. Fibrin provides a scaffold in which t PA and 
plasminogen are held in such a way that the activity of t PA is increased 
manyfold. Accelerated dose  of  tPA  is preferred ,where it is administered over 
a period of 90 minutes. Modification in the native  structure of t PA led to the 
discovery of newer fibrinolytic agents that have increased plasma clearance 
allowing bolus dosing. These agents include alteplase, tenecteplase and 
reteplase. Streptokinase ,a protein secreted by streptococci ,is an inexpensive 
fibrinolytic agent which is used in developing countries. It is fibrin non specific. 
 
 
 
 
 
 
 
 
 
Fig 6 : Molecular Structure of Different Fibrinolytics 
 Table 1: Comparison of approved fibrinolytic agents 
FIBRINOLYTIC 
AGENT 
DOSE FIBRIN 
SPECIFICITY
FIBRINOGEN 
DEPLETION 
ANTIGENIC
Tenecteplase Single iv 
weight 
based bolus 
++++ minimal - 
Reteplase(r PA) 10 units + 
10 units iv 
boluses 30 
min apart 
++ moderate - 
Alteplase (t PA) 90 min wt 
based 
infusion 
++ mild - 
Streptokinase 1.5 million 
units iv 
over 60 
mins 
No marked + 
 
 
 
 
 TENECTEPLASE: 
   Bolus of 30 mg for weight less than 60 kg, 35 mg for 60 to 69 kg, 40 mg 
for 70 to 79 kg, 45 mg for 80 to 89 kg, and 50 mg for 90 kg or greater. 
 
ALTEPLASE: 
   Bolus of 15 mg, infusion of 0.75 mg/kg for 30 minutes (maximum, 50 
mg), then 0.5 mg/kg (maximum, 35 mg) over the next 60 minutes; the total dose 
not to exceed 100 mg.  
 Fibrinolytics of differ in their molecular structure and biochemical action 
but they seem to be more equivalent in their clinical complication and biological 
activity. All these drugs degrade the thrombus through plasmin, resulting in 
hypocoaguability. They are usually given in infusions and the duration of 
infusion is inversely proportional to the half life of the compounds. After 
therapy is discontinued there is a hypocoaguability due to reduced fibrinogen in 
the plasma and this continues till the activator is eliminated from the blood 
.Coagulation and platelet may be transiently increased after administration of 
the agent. Within the initial hours coronary reperfusion can be achieved with 
almost all thrombolytics (50 – 60 % of all patients).With greater hour of 
thrombus the efficacy is better with rt-PA than streptokinase. However 
reocclusion is commoner with rt-PA than streptokinase. Anti-platelet agents 
have greater additive role in preventing re-occlusion when used along with 
 thrombolytics and they have shown mortality benefit too. Intracranial bleeding 
and cerebrovascular accident are the most common side effect of thrombolytic 
use. If the patient presents more than 12 hours, the risk of bleeding outweighs 
the benefit from thrombolysis.Failure rates will also be very high. In cases of 
failure of the therapy the patient is treated conservatively with anticoagulants to 
complete the infarct or may be advised to undergo percutaneous coronary  
intervention. 
PERCUTANEOUS CORONARY INTERVENTION:  
 Primary PCI when performed can open the infarct related artery in around 
95 % of cases compared to spontaneous recanalisation of arteries. Primary PCI 
includes performing coronary angiogram to identify the occluded vessel 
followed by angioplasty to open up the infracted artery. 
 
 ASSESSMENT OF REPERFUSION : 
The TIMI flow grade 
The TIMI  frame count 
Myocardial perfusion 
 
 
 
  
 
Electrocardiography : 
 The extent of ST-segment resolution provides powerful prognostic 
information early in the management of patients with STEMI 
Non invasiveimaging :  
Myocardial contrast enhanced echocardiography 
 
Invasive imaging : Doppler flow wire studies 
                       In ECG successful thrombolysis can be assessed by : ECG should 
be obtained immediately after 30 minutes of completion of thrombolysis. 
Resolution of ST segment elevation by more than 70 % of the previous ecg 
                       Relief of chest pain 
                       Return of hemodynamic stability 
                       Presence of  reperfusion arrhythmias 
 In the presence of failed thrombolysis patients should be immediately 
advised for Rescue PCI. 
  Even in the presence of successful thrombolysis patient should be 
advised for Coronary angiogram to identify the culprit vessel and to remove any 
residual plaque. Patients can be advised for CAG immediately after lysis with 
tenecteplase  but should wait for atleast 1 day following lysis with 
Streptokinase. 
  Increased focus is now been laid on secondary prevention of acute 
coronary syndromes which includes 
• Risk factor modification 
• Diet modification and ideal body weight maintenance 
• Hypertension management 
• Hypercholesterolemia management 
• Exercise 
• Diabetes management 
DIABETES  MELLITUSAND CORONARY ARTERY DISEASE : 
    Diabetes mellitus is characterised by recurrent or persistently elevated blood 
sugar and diagnosed by one of the following  
“  1. fasting plasma glucose level greater than or equal to 7 mmol/l or 126 mg/dl 
    2.  Plasma glucose greater than or equal to 11.1 mmol/l or 200 mg/dl 2 hours 
after a 75g oral glucose load in a glucose tolerance test 
 3. Symptoms of high blood sugar plus a random plasma glucose greater than or  
equal to 11.1 mmol/l or 200 mg/dl 
4. Glycated haemoglobin (HbA1c ) greater than or equal to 6.5%” 
 
 Besides diabetes ,diabetics present with other cardiovascular risk factors 
like hypertension, dyslipidemia, atherosclerosis etc. But beyond this clustering 
there are numerous other implicated mechanisms in the increased risk among 
 patients with diabetes. There is a clear association between the severity of 
hyperglycemia and cardiovascular mortality. 
            The vascular injuries seen in diabetes include autonomic dysfunction, 
effects of circulating reactive oxygen species fatty acids, adverse effects of 
advanced glycation end products , and increase in the systemic mediators of 
inflammation. Exposure to increased insulin therapy,  sympathovagal imbalance 
also contributes to atherosclerotic risk.The various contributing factors in 
diabetic patients leading to atherosclerosis include: 
 
ENDOTHELIUM:  
↑ NF-κB activation 
↓ Nitric oxide production 
↓ Prostacyclin bioavailability 
↑ Endothelin 1 activity 
↑ Angiotensin II activity 
↑ Cyclooxygenase type 2 (COX-2) activity 
↑ Thromboxane A2 activity 
↑ Reactive oxygen species 
↑ Lipid peroxidation products 
↓ Endothelium-dependent relaxation 
↑ RAGE expression 
 
  
Vascular smooth muscle cells and vascular matrix: 
↑ Proliferation and migration of vascular smooth muscles into intima 
↑ Incresed degradation of matrix. 
 
Altered matrix components: 
Inflammation ↑ IL-1β, IL-6, CD36, MCP-1 
↑ ICAMs, VCAMs, and selectins 
↑ Activity of protein kinase C 
↑ AGEs and AGE-RAGE interactions 
 The injurious effects of  hyperglycemia can be divided into microvascular 
and macrovascular complications. 
MACROVASCULAR COMPLICATIONS: 
     Diabetes is a major risk factor in the development of 
atherosclerosis. Atherosclerotic lesion plays a major role in macrovascular 
complications. 
This includes 
a) Ichemic cardiovascular disease 
b) Peripheral arterial disease 
c) Cerebrovascular disease 
 
 MICROVASCULAR COMPLICATIONS: 
a) Eye – Retionopathy (proliferative and non proliferative) 
          Macular edema 
b) Neuropathy –mainly small fibre neuropathy both sensory and motor 
Mononeuropathy and polyneuropathy 
c) Nephropathy  
 Microvascular complications  should be screened immediately for type 2 
diabetics and can wait for 5 years in type 1 diabetics. 
Genetic factors appear to contribute to the susceptibility to microvascular 
disease. 
CAD AND DIABETES : 
                   Coronary artery disease accounts for nearly 80% of deaths in 
patients with diabetes. Once recognised as a disease of adulthood it is now 
frequently seen in adolescent population. There are more women diabetics   
than males. Patients with diabetics have a varied presentation of symptoms of 
myocardial infarction usually without chestpain. Hence the term silent 
infarction is used. The risk of cardiac failure and other postmyocardial 
infarction complications is also high in diabetics. They present with massive 
infarction compared to non- diabetics. This increased mortality and morbidity 
 may be attributed to the chronic hyperglycemia seen in diabetes per se rather 
than the associated comorbid conditions. 
 Atherosclerosis play the central role in the macrovascular complications 
of diabetes. It involves blood vessels in the periphery as well as coronary blood 
vessels. In coronary vasculature there is more diffuse and severe stenosis of 
blood vessels and more severe left main disease. In diabetics there is an increase 
in the expression of adhesion molecules on the endothelial surface. This causes 
the endothelium to become more adherent to passing cells in the bloodstream. 
The leucocytes get attached  through selectins on their surface to the vascular 
endothelium. The monocytes get attached to the endothelium and transform into 
macrophages. They take up oxidised LDL to become macrophage foam cells. 
There is a significant reduction in the activity of nitric oxide in diabetic patients. 
Nitric oxide is essential for normal functioning of vascular endothelium. When 
it is reduced there is increased activation of adhesion molecules, leucocyte 
infiltration, reduced vasodilatation, platelet aggregation and thrombosis. The 
increased oxidative stress ,high circulating lipids, elevated blood glucose levels 
adversely affects nitric oxide synthesis and function. 
                   Platelet function is also highly abnormal in diadetics. There is 
increase in the expression of glycoproteins on the platelet surface, increased 
activation and adhesion. Many clotting factors are also upregulated in diabetics. 
 FactorVII, thrombin, tissue factor and plasminogen activator inhibitor I are seen 
in diabetics  increases the tendency towards thrombus formation. 
                Other independant  ardiovascular risk factors also cluster in diabetics. 
Metabolic syndrome is common in diabetics. Because of this diabetes is now 
considered as a cardiovascular disease equivalent rather than an individual risk 
factor 
 
PLATELETS : 
 Platelets also known as thrombocytes are discoidal blood cells that 
participate in hemostasis. On a stained blood smear , platelets are dark purple in 
colour  about  1/5 th the diameter of  red blood cells. They are anucleated and 
are found only in mammals. The ratio of  platelets to red blood cells in adults is 
1 : 10 to 1: 20.The main function of platelets is the formation of primary 
hemostatic plug: they gather at the site of  interrupted endothelium and plug the 
hole. The process includes 
adhesion  – the platelet attach to substance outside the injured endothelium 
activation–they change their structural configuration, secrete chemical 
messengers and turn on receptors. 
Aggreggation-platelets connect with one among themselves. 
 Once the primary hemostasis is achieved ,coagulation cascade is activated 
leading to the formation of the fibrin clot (secondary hemostasis) Structurally 
platelets have 4 zones from outside to inside 
 1.Peripheral zone : This zone is abundant in glycoprotein required  for platelet 
function ( i.e  GP II b/III a ;GP Ib/ IX ;GP VI ) 
2.Solgel zone : This layer has microfilaments and microtubules, which help the 
platelets to maintain their shape and structure. 
3.Organelle Zone : This zone is rich in platelet granules. Alpha granules 
contain clotting factors like factor V, VIII, I, fibronectin, PDGF. Delta granules 
contain platelet activating mediators like ADP, calcium and serotonin. 
4.Membranous zone : This zone  is responsible for thromboxane A2 synthesis. 
 
           Megakaryocyte and platelet production is regulated by thrombopoetin 
which is synthesised in liver and kidney. A megakaryocyte  produces 1000 to 
3000 platelets during its lifetime. The average lifespan of   platelets is 7 to 9 
days. 
FUNCTIONS OF PLATELTS: 
• Prevention of bleeding through formation of hemostatic plug. 
• The contractile proteins in platelets causes clot retraction.  
• Activation of clotting cascade through the intrinsic mechanism. 
• Secretes various vascular growth factors which helps in the growth of 
endothelial and vascular smooth muscle cell following injury. 
 
 MECHANISM OF FORMATION OF PRIMARY HEMOSTATIC 
PLUG : 
 At  the site of vascular injury ,platelets get attached to the underlying 
exposed collagen. After attachment platelets change their morphology. Then 
the alpha and delta granules are released from the platelet surface.ADP is 
released from the platelet granules which causes the aggregation of platelets. 
 The platelets which are aggregated adhere to the von willebrand factor. 
Following this there is more release of ADP and more aggregation  of 
platelets. Platelet aggregation is more reinforced by the release of 
Thromboxane A2 which causes even more aggregation and more release of 
ADP. This leads to the formation of primary hemostatic plug 
 The aggregated platelet plug not only physically seal the break in the 
vessel but, also perform three other important roles: 
 
• Actin and myosin present in the platelets by contracting strengthens the 
primary hemostatic plug. 
• Secondly, various chemicals released from the  platelet plug include several 
vasoconstrictors (serotonin, epinephrine and Thromboxane A2 ) cause 
vascular vasospasm  
• They aid in blood clotting 
 
 
  
 
 
 
 
 
 
          
Fig 7:Functions of platelets 
 
      Prostacyclin generated in the vascular endothelium prevents platelet 
aggregation and prevents the spread of spread of platelet plug to the normal 
vessel wall 
PLATELET ACTIVITY AND DIABETES : 
 The metabolic complications seen in diabetes maybe  attributed to the 
increased platelet activity seen in this metabolic condition. The micro and 
macrovascular complications seen in diabetics is attributed  to altered platelet 
morphology  and function. Platelet  hyperactivity and increased baseline 
activation which is seen in diabetes is multifactorial. There is also an increased 
surface expression of glycoprotein receptors and increase in the production of 
growth factors. There is non enzymatic glycation of proteins on the surface of 
platelets, by the osmotic effect of glucose  and by the activation of protein 
 kinase C. Membrane fluidity is altered by this mechanism and this results in 
increased platelet activity .Insulin also regulates platelet activity via functional 
Insulin Receptor found in human platelets. Superoxide released during 
inflammation increases intraplatelet release of  calcium after their activation and 
increasing their reactivity. Superoxide  also inhibits nitric oxide activity and 
prostacyclin production .Platelets from diabetics have increased expression P 
selectin and Gp II b/III a receptor and more sensitivity to stimulation from 
agonist than non diabetics. 
            Platelet activation causes thrombosis and microcapillary embolisation 
with release of constrictive, mitogenic substances like PDGF and VEGF. 
 
 
 
 
 
 
 
 
 
 
 
Fig 8:Platelets in CAD patients          
 MATERIALS AND METHODS: 
STUDY POPULATION: 
  This study is to be conducted among 100 patients diagnosed with 
STEMI admitted in ICCU within 12 hours of onset of symptoms at 
Kanyakumari Government Medical College hospital 
 
INCLUSION CRITERIA   
y Patients admitted with diagnosis of STEMI within 12 hours from the 
onset of symptoms. 
 
EXCLUSION CRITERIA: 
y Co existing autoimmune diseases 
y Acute / chronic infectious /inflammatory diseases 
y Known malignant diseases 
y Use of  steroids 
y Admission platelet count below 100 & above 4.5 lakh cell/mm^2 
 
 
 
 
 
 
 METHODOLOGY: 
Patients admitted with ST elevation MI admitted within 12 hours of the onset of 
symptom were enrolled 
             Venous blood samples were collected immediately after admission prior 
to the administration  of anti platelet therapy in standardized dipotassium 
ethylene dinitro acetic acid (EDTA tubes) 
               Samples were tested within 30 minutes of  collection to minimize 
variations due to sample ageing 
 Diabetes was defined as 
1) Pre existing diabetes diagnosed prior to admission for STEMI ( 
patient on insulin, OHAs or diet) 
2) Newly diagnosed diabetes mellitus based on fasting plasma glucose 
levels. Fasting plasma glucose levels were checked on the third day 
of admission to avoid stress hyperglycemia 
STEMI was defined by : 
ST segment elevation consistent with MI of 2 mm in contiguous 
precordial leads and or ST segment elevation of 1 mm in  two or more 
contiguous limb leads or new onset left bundle branch block 
             Patients are  treated with 300 mg of aspirin & 300 mg of clopidogrel 
and subjected to  thrombolysis with streptokinase  
 
 
               Successful thrombolysis is defined as ST segment resolution > 50% of 
the original and or symptomatic relief of chest pain. 
 Admission time Random blood glucose was taken initially to screen 
diabetics and non diabetics, followed by fasting plasma glucose on day  once 
the patient stabilises. 
              Since cardiac troponin assay was not available in our setting, CK MB 
measured with a mass assay was carried out. 
Echocardiogram was taken on the third day after thrombolysis to evaluate left 
ventricular systolic and diastolic functions and other associated complication. 
Patients were followed up for a period of 1 month for mortality & morbidity. 
Repeat Echocardiogram is  done after 1 month for the evaluation of patient ‘s 
cardiac status 
Interested patients may be subjected to Angiographic evaluation. 
 
ANTICIPATED OUTCOME: 
 Diabetic patients are expected to have high MPV than non diabetics.    
 Both in diabetic and non diabetics MPV proved to have good prognostic 
value for in-hospital and 1 month mortality                                                                                 
 Diabetic patients are expected to have higher mortality at lower MPV 
values than non diabetic 
 
 
 STATISTICAL ANALYSIS : 
 
                    Analysis was done using SPSS 16.0 software. Data were expressed 
in terms of percentages, mean values with standard deviation or median values. 
Differences between the groups were analyzed using Mann Whitney U test for 
median and chi square test for proportions. The association of each predictor 
variable with NAFLD was assessed using Simple Linear Regression models. 
Results were said to be statistically significant if the p value was less than 0.05. 
 
RESULTS : 
              In our total study population out of 100 who presented with acute 
STEMI , 41 were diabetic and 50 were non diabetic. The age pattern of the 
study population is given in table 1.Most of the patients  belonged to the age 
group 50 to 70 years. There were 64 males and 36 females in the study. 
 
 Oldest Patient recorded -33 years 
Youngest patient recorded- 90 years 
 
 
 
 
 
 DISCUSSION 
PATIENT CHARACTERISTICS : 
 
Table 2: Patient Characteristics 
 
Characteristics Number of patients 
Male 64 
Female 36 
Smokers 24 
Alcoholics 4 
Patients with prior cad 15 
Hypertensives 36 
Infarct wall Ant wall – 60 
Inferior wall – 33 
Inf wall ,post wall &right ventricle – 3 
Ant wall &inf wall -2 
 
 
  
Table 3: Age distribution of the study population 
 
 
 
 
 
 
 
 
 
Fig 8:  Bar diagram showing age distribution 
The patients who presented with STEMI clustered in the age group above 50 
years with maximum incidence in the age group 51 to 60 years. 
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Total no of Acute MI patients who were diabetics : 42 
Total no of Acute MI patients who were non diabetics : 58    
 
Table 3: SEX DISTRIBUTION AMONG DIABETICS AND NON DIABETICS 
 
              In our study, among diabetics 59.52 % were males and 40.47 % were 
females. Among the total males presented 39.06 % were diabetic and among the 
total female presented 47.22 % were diabetics. This shows that among the 
patients presented with MI the incidence of diabetes was higher among females 
in our study 
 
 NO OF 
MALES 
% OF MALES 
 
NO  OF 
FEMALES 
% OF 
FEMALES 
DIABETICS 25 
 
 
59.52 % 17 40.47 % 
NON 
DIABETICS 
40 68.96 % 18 31.03 % 
 Table 4: HbA1C value among diabetics and non diabetics 
 
 
 
 
 
 
Fig 11: Mean HbA1C value among Diabetics & Non Diabetics 
The mean HbA1c values were significantly higher in diabetics compared to non 
diabetics. The average value was 8.08 for diabetics and 5.83 in non diabetics. 
The p value of this test is also clinically significant . 
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 Table 5: Mean Platelet volume among Diabetics and Non Diabetics 
 
 
 
 
 
 
 
Fig 12: Mean Platelet volume among Diabetics and Non Diabetics 
The mean platelet volume was significantly higher among diabetics. The p 
value of the test was p< 0.0001.This study confirms the hypothesis that the 
platelets in diabetics are large and hyperactive . 
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Table 7: Mortality among Diabetics and Non Diabetics 
 
 
 
 
 
 
Fig 14: Mortality among Diabetics and Non Diabetics 
 Diabetics had higher mortality than non diabetics. Both in patient 
mortality and mortality during 1 month follow up was higher in diabetics. 
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Table 8: Sex wise Mortality distribution among Diabetics and Non Diabetics 
  No of males 
expired 
% of  males No of females 
expired 
% of 
females 
Diabetics 8 50% 8 50% 
Non diabetics 4 80% 1 20% 
 
 Among the total 21 deaths , 16 were diabetic and the remaining 5 were 
non diabetics. Among diabetic deaths 8 were males and 8 were females. Among 
non diabetics 4 were males and 1 was female 
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 Table 11: KILLIP class among Diabetics and Non Diabetics 
 
 
 
 
 
 
Fig17: KILLIP class among Diabetics and Non Diabetics  
 The study shows that diabetics presented with higher killip on admission 
than non diabetics. With Killip class presentation there were more non diabetics 
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 Table 12: KILLIP class and Mortality 
 
 
 
 
Table 13: TIMI Score and Mortality 
 
 
 
 
 Our study shows strong correlation between higher KILLIP class and 
TIMI score on admission with mortality. The p value of the test is also 
significant 
 
 
 
 
KILLIP 
Score 
Correlation 
Coefficient
p 
value 
Mortality 0.253 0.004 
TIMI 
Score 
Correlation 
Coefficient p value 
Mortality 0.242 0.012 
 Table 14: Mortality and Higher Mean platelet volume 
 
Mortality 
Correlation 
Coefficient p value 
MPV 0.065 0.433 
 
                  There is also correlation between Mean Platelet volume and 
mortality thus proving our hypothesis 
Table 15: Mortality comparison between diabetics and non diabetics with 
admission MPV 
 
Mortality 
Correlation 
Coefficient p value 
DM -0.057 0.669
NON-DM -0.09 0.414
 
              However correlation could not be reached for mortality among 
diabetics and non diabetics with admission MPV value. This may be due to the 
small sample size we enrolled in this study 
  
In our study : PROGNOSTIC SIGNIFICANCE OF MEAN PLATELET 
VOLUME IN PATIENTS PRESENTIN WITH  ST ELEVATION 
MYOCARDIAL INFARCTION conducted at Kanyakumari Government 
Medical College Hospital analysing 100 patients presenting to ICCU with acute 
STEMI has elucidated many findings. 
DEMOGRAPHY OF THE POPULATION : 
                 In 100 patients with acute MI, 36 % were females and 64 % were 
males. The number of diabetics were 42 and non diabetics were 58.  Among 
diabetics 59.52 % were males and 40.47 % were females. Among the total 
males presented 39.06 % were diabetic and among the total female presented 
47.22 % were diabetics which showed that among the females presented the 
incidence of diabetes is higher in them compared to males. Higher incidence of 
MI was noted in the age group of 51 to 60 years with overall clustering of cases 
seen above the age group of 50 years. 
     According to NCEP ( National Cholesterol Education Programme ), 
decades of observational meta analysis of various studies have clearly shown 
that the incidence of MI is higher in males compared to pre menopausal women. 
However after menopause the risk remains the same. 
                 This is clearly demonstrated in our study. Among the females 
presented only 3 were under 50 years of age and with only one female below 45 
years of age. The remaining 23 were above 50 years of age. 
Among the patients presented diabetics had higher HbA1c values compared to 
non diabetics. The mean HbA1c was 8.08 for diabetics and 5.83 for non 
diabetics. Diabetics also presented with higher mean platelet volume. The 
average MPV for diabetics was 9.94 fl and for non diabetics was 9.06 fl.   
              According to a study conducted by Dr. Thomas Alex Kodiatte et all, 
Departments of Pathology and 1Medicine, Sri Devaraj Urs Medical College, 
Tamaka, Kolar, India named Mean Platelet Volume in type 2 Diabetes Mellitus, 
which showed that in diabetic patients the MPV was significantly higher than 
that seen in non diabetics ( p value < 0.0001 ).Among the diabetic subjects a 
positive Pearson correlation was seen between MPV and HbA1c. 
              This finding is confirmed in our study with high statistical significance. 
There is a positive correlation between admission MPV and HbA1c value ( r – 
0.34 ; p value < 0.0001 ) 
              A correlation could not be reached between admission CK MB values 
among diabetics and non diabetics. CKMB mass assay is not a highly specific 
test for myocardial ischemia and its sensitivity and specificity is less compared 
to cardiac troponins. The p value was >0.05  
 
 Mean platelet volume and mortality and mortality indices : 
              In our study Mean platelet volume positively correlated with mortality 
indices like TIMI score and KillipScore. In our study , TIMI score had a 
positive correlation with MPV in Pearson correlation test( r -0.189 and p value – 
0.059),and KILLIP score had a strong correlation with MPV in Pearson 
correlation test ( r – 0.238 and p value – 0.017). 
             According to a study conducted by Andrzej Lekston et all, Third 
department of cardiology, Poland , it was shown that the Mean platelet volume 
positively correlated with admission KILLIP class which was proved in our 
study also 
Individual risk factors like systemic hypertension, prior CAD was not analysed 
separately as they were statistically evaluated via the TIMI score which predicts 
14 day mortality in patients presenting with acute MI. 
            Comparing the correlation between admission MPV and overall 
mortality (both in hospital and one month mortality taken together ) our study 
showed a correlation between the two variables. According to Kendall Tau’s 
test, by which the above parameters were analysed it showed a correlation 
coefficient value of 0.065 and a p value of 0.433.  Then comparing mortality 
among diabetics and non diabetics, the mortality was higher in diabetics than 
 non diabetics with a p value of  < 0.0001.Both in patient and 1 month follow up 
mortality was significantly  higher in diabetics. 
             Many studies have highlighted this finding emphasizing that diabetics 
have a higher mortality. In the study conducted by Andrzej Lekston et all, Third 
department of cardiology, Poland, the findings wee postulated as : diabetic 
patients have a higher MPV value than non diabetics; MPV value serves as a 
good prognostic indicator of long term mortality; MPV values correlated 
positively correlated with admission hemodynamic status; overall mortality 
higher for higher MPV values 
          Another study published in JACC, done by Zeron Huczeck et all, Poland 
it is shown that there is positive correlation between admission MPV value and 
no reflow phenomenon and slower CTFC values, with patients with higher  
baseline values of MPV showing no reflow phenomenon. 
              Our study too supports many of these findings with mortality higher 
with higher MPV values, diabetics having higher MPV values, MPV values 
positively  correlating  with admission hemodynamic status which is  assessed 
by KILLIP score. 
          KILLIP score and TIMI score independently had strong correlation with 
mortality : with higher admission scores having higher mortality. This has been 
proved by many studies. 
                   In our study we could not arrive at a statistically significant 
correlation between MPV value among diabetics and mortality in comparison 
with MPV values among non diabetics and mortality. This drawback would 
have been due to the limited sample size of our present study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
         Cardiovascular diseases account for vast majority of mortality and 
morbidity in developing countries. Acute Coronary Syndrome which is a major 
cause of cardiovascular mortality  encompasses a spectrum of conditions 
namely : unstable angina, NSTEMI and STEMI. 
                  Various risk factor assessment tools and mortality predictors have 
been developed for STEMI. Among these in this study we evaluated the role of 
Mean  Platelet Volume in predicting overall mortality in patients presenting 
with acute MI. 
            Diabetics presenting with acute MI had higher MPV values than non 
diabetics. This has been proven in many studies and our study also confirms 
that. In addition cardiovascular mortality was also higher in diabetics compared 
with non diabetics This is due to the fact that the platelets in diabetics are larger 
and more reactive. 
               MPV values in our study showed positive correlation for mortality, 
admission TIMI score and admission KILLP class. This finding emphasizes the 
fact that Mean Platelet Volume can be used an independent and cheap indicator 
for predicting overall cardiovascular mortality. 
 
 
                                              CONCLUSION 
• Mean Platelet Volume was higher in diabetics than non diabetics 
• Mean platelet Volume has positive correlation with overall  mortality 
;mortality rate higher with higher MPV values 
• Mean Platelet Volume correlated with admission hemodynamic status 
which is assessed by KILLIP class and TIMI score 
• Mean platelet volume had significant correlation with HbA1c values 
• Mean Platelet Volume can be used as a predictor of long term 
cardiovascular mortality. 
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 PROFORMA 
 
Performed by:                                       date 
Name :   Age/Sex:  Occupation: 
Ht :  wt    :           BMI : 
  Ward                           IP NO 
Diagnosis 
Presenting complaints: 
 
Past history: 
          H/o DM, HIV, PT, HT, CKD, CVD, COPD etc 
Diabetes (y/N)                     duration 
 
Clinical examination: 
 
General examination: 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,  
 
Vitals: PR, BP,Temp, RR, SpO2,JVP,Heart rate 
 
TIMI SCORE                             KILLIP CLASS 
 
 Systemic examination:  CVS:   RS:  Abd:   CNS: 
Laboratory investigations: 
Mean platelet volume 
Platelet count 
Complete blood count 
RBS,FBS,PPBS 
ECG 
ECHO: 3 rdday and after 1 month 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
CAD   - Coronary Artery Disease 
CVD - Cardiovascular disease 
MPV – Mean Platelet Volume 
STEMI – ST segment Elevation Myocardial Infarction 
TIMI – Thrombolysis In Myocardial Infarction 
DM – Diabetes Mellitus 
IL – interleukin 
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